Henry ScheinRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Henry Schein (HSIC) reported revenue of $3.46B in Q2 2026, with Healthcare Distribution its largest revenue segment at 93%.
Henry ScheinHenry Schein distributes products, services, and technology to office-based dental and medical practitioners. It serves more than 1 million customers from Melville, New York, and employs more than 25,000 people.
Henry Schein (HSIC) is a Health Care Distributors company. Henry Schein distributes products, services, and technology to office-based dental and medical practitioners. It serves more than 1 million customers from Melville, New York, and employs more than 25,000 people. It was founded in 1932, is headquartered in Melville, New York and employs about 25,000 people.
As of 2024-Q3, Henry Schein's revenue breaks down across Healthcare Distribution (93%), Technology (7%). See the revenue-by-segment chart for the full mix.
Track Henry Schein's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.
Sterling groups Henry Schein in the Healthcare sector, alongside Biogen (BIIB), Gilead Sciences (GILD), Incyte (INCY), Vertex Pharmaceuticals (VRTX), Abbott Laboratories (ABT) and Baxter International (BAX).
If you are researching Henry Schein, also look at Biogen (BIIB), Gilead Sciences (GILD) and Incyte (INCY). You can compare all of them side by side or browse the full Healthcare sector on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026